Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 12/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1955382 | 0.94 | BCL2 (0.80) | BCL2 | |
| SCHEMBL1955458 | 0.88 | BCL2 (0.86) | BCL2 | |
| SCHEMBL1957662 | 0.85 | BCL2 (0.88) | BCL2 | |
| SCHEMBL1957943 | 0.82 | BCL2 (1.00) | BCL2 | |
| Trifluoroacetic Acid SCHEMBL1959881 | 0.81 | BCL2 (0.93) | BCL2 | |
| Trifluoroacetic Acid SCHEMBL1959880 | 0.81 | BCL2 (0.93) | BCL2 | |
| SCHEMBL1959331 | 0.80 | BCL2 (0.65) | BCL2 | |
| SCHEMBL19424703 | 0.80 | BCL2 (0.59) | BCL2 | |
| SCHEMBL1958063 | 0.79 | BCL2 (0.97) | BCL2 | |
| SCHEMBL1956610 | 0.79 | BCL2 (0.70) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315488-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160009687-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009687-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | BCL2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.